Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.
- Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.
- Gross Margin improved to 76% for the quarter, up from 43% for the same period last year.
- Heron to host its first ever Investor Day event on Wednesday, May 15, 2024 in New York, New York.
- SAN DIEGO, May 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.